Loading clinical trials...
Loading clinical trials...
The Regional Pediatric Network and the Use of Low-cost Molecular Diagnostic Techniques Cost as a New Management and Surveillance Model for Diseases Preventable by Vaccinations.
Vaccine-preventable disease (VPD) surveillance should be a priority throughout the world. In Italy, however, there is limited attention to the epidemiology of VPDs, with the consequence that their incidence is largely underestimated. Although notification of vaccine-preventable diseases is mandatory, very often the etiologic agents causing VPDs are not identified the etiological agents causing the major and most severe infectious diseases in childhood. Several reasons underlie the underestimation. For example, not having a good surveillance system does not allow us to organize a sustainable prevention project for example based on on the introduction of new vaccinations. For example the limited use of low-cost high-sensitivity techniques such as real-time PCR, which could, if more widely used, improve pathogen identification with 3 times the sensitivity of standard cultural methods. Therefore, the idea of this multicenter, biological sample study is to take advantage of the regional pediatric network with the goal of improving VPD surveillance and increase awareness of the importance of surveillance of preventable diseases with the vaccine within the pediatric network.
Age
0 - 18 years
Sex
ALL
Healthy Volunteers
No
Ospedale San Donato
Arezzo, Italy
Immunology Laboratory Meyer Children's Hospital, IRCCS
Florence, Italy
Meyer Children's Hospital IRCCS
Florence, Italy
UO Pediatria Universitaria Ospedale S.Chiara
Pisa, Italy
Start Date
May 4, 2021
Primary Completion Date
February 28, 2025
Completion Date
March 31, 2025
Last Updated
March 21, 2024
1
ESTIMATED participants
Analysis of biological sample
OTHER
Lead Sponsor
Meyer Children's Hospital IRCCS
NCT04263792
NCT06135350
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06319235